Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T11:05:27.037Z.
Consensus retrieved: 2026-10-06T09:01:14.876Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T11:05:27.037Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3b719543d2ad964e34cebd38a4954272106044749b474b483c00e469aab85807
FORWARD PE RATIO
N/A
Ascendis Pharma A/S
Market Cap
$14.16B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Ascendis Pharma A/S (ASND) | $14.16B | N/A |
| Tempus AI, Inc. (TEM)vs › | $14.64B | N/A |
| Exelixis, Inc. (EXEL)vs › | $14.79B | 16.75 |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.97B | 27.39 |
| Corcept Therapeutics Incorporated (CORT)vs › | $13.19B | N/A |
| Solventum Corporation (SOLV)vs › | $15.24B | 12.29 |
| BridgeBio Pharma, Inc. (BBIO)vs › | $12.95B | N/A |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 15.90 |
| Baxter International Inc. (BAX)vs › | $12.52B | 11.79 |
| Penumbra, Inc. (PEN)vs › | $12.49B | 67.36 |
Trailing P/E
17.3
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
Consensus estimates for this stock are reported in EUR, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
